이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

유전성 평활근종증 신세포암 - 신장암의 유전적 원인과 소인에 관한 연구

2026년 11월 7일 업데이트: National Cancer Institute (NCI)

유전성 평활근종증 신세포암(HLRCC): 질환 유전자 규명 및 신장암 소인 특성 규명

This study will investigate what causes hereditary leiomyomatosis renal (kidney) cell cancer, or HLRCC, and how the disease is related to the development of kidney tumors. Leiomyomas are benign (non-cancerous) tumors arising from smooth muscle. HLRCC can cause various health problems. Some people develop red bumps on their skin that can be painful at times. Some women with HLRCC can develop leiomyomas of the uterus. In some families, people with HLRCC develop kidney tumors. This study will try to determine:

  • What gene changes (mutations) cause HLRCC
  • What kind of kidney tumors develop in HLRCC and how they grow
  • What the chance is that a person with HLRCC will develop a kidney tumor

People with known or suspected HLRCC (and their family members of any age) may be eligible for this study. This includes people in families in which one or more members has skin leiomyoma and kidney cancer; skin leiomyoma and uterine leiomyoma; multiple skin leiomyomas; kidney cancer and uterine leiomyomas, or kidney cancer consistent with HLRCC, including, but not limited to, collecting duct or papillary, type II. Candidates will be screened with a physical examination, family history, and, for affected family members, a review of medical records, including pathology slides and computed tomography (CT) or magnetic resonance imaging (MRI) scans.

Participants will undergo tests and procedures that may include the following:

  • Review of medical records, x-rays, and tissue slides

  • Physical examination and family history

  • Skin examination

  • Gynecological examination for women

  • Interviews with a cancer doctor, cancer nurses, kidney surgeon, and genetic counselor

  • Blood tests for:

    1. Genetic research to identify the gene responsible for HLRCC
    2. Evaluation of liver, kidney, heart, pancreas, and thyroid function
    3. Complete blood count and clotting profile
    4. Pregnancy test for pre-menopausal women
    5. PSA test for prostate cancer in men over age 40
  • CT or MRI scans (for participants 15 years of age and older only)

  • Skin biopsy (surgical removal of a small sample of skin tissue)

  • Cheek swab or mouth rinse to collect cells for genetic analysis

  • Medical photographs of lesions

  • Questionnaire

When the tests are completed, participants will discuss the results with a doctor and possibly a genetic nurse or genetic counselor. The genetic findings will not be revealed to participants because their meaning and implications may not yet be understood. Participants may be asked to return to NIH from every 3 months to every 3 years, depending on their condition, for follow-up examinations and tests.

연구 개요

상태

모병

정황

상세 설명

Background:

  • Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is a rare autosomal dominantly inherited disorder which confers susceptibility to develop cutaneous and uterine leiomyomas and renal cell carcinoma.
  • HLRCC is caused by mutations in the Krebs cycle enzyme, fumarate hydratase localized on chromosome 1q42.3-q43.

Objectives:

  • Define the risk of developing renal cancer, cutaneous leiomyoma and uterine leiomyoma in this hereditary cancer syndrome
  • Define the types and characteristics (including patterns of growth) of renal cancer associated with HLRCC
  • Determine the incidence and characteristics of HLRCC-associated fumarate hydratase gene mutations
  • Determine genotype/phenotype correlations
  • Determine if other genes cause HLRCC

Eligibility:

  • Individuals that meet one or more of the following criteria:

  • Suspected or known to have phenotype or genotype suggestive of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC), such as:

    • Cutaneous leiomyoma and kidney cancer
    • Cutaneous leiomyoma and uterine leiomyoma
    • Multiple cutaneous leiomyoma
    • Kidney cancer and uterine leiomyomata

or

-Renal tumor histology consistent with HLRCC including, but not limited to: Collecting Duct and/or Papillary, Type II

or

-Are a relative (related by blood) of an individual with a confirmed or suspected diagnosis of HLRCC

Design:

  • These rare biological families will be recruited to genetically confirm diagnosis, determine size and location of renal tumors, size at presentation, growth rate and metastatic potential of renal tumors.
  • Genetic testing will be offered to gain appreciation of the effect of mutations on the relative activity of various germline and somatic mutations.
  • We will determine if there is a relationship between mutation and disease phenotype.

연구 유형

관찰

등록 (추정된)

1350

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Maryland
      • Bethesda, Maryland, 미국, 20892
        • 모병
        • National Institutes of Health Clinical Center
        • 연락하다:
          • For more information at the NIH Clinical Center contact National Cancer Institute Referral Office
          • 전화번호: 888-624-1937

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

2년 이상 (어린이, 성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

An individual (including patient) from a family in which one or more family member have: cutaneous leiomyoma and kidney cancer, cutaneous leiomyoma and uterine leiomyoma, multiple cutaneous leiomyoma, kidney cancer and uterine leiomyomata, renal tumor histology consistent with HLRCC including, but not limited to: Collecting Duct and/or Papillary, Type II.

설명

  • INCLUSION CRITERIA:

  • Individuals that meet one or more of the following criteria:

    • Suspected or known to have phenotype or genotype suggestive of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC), such as:

      • Cutaneous leiomyoma and kidney cancer; or
      • Cutaneous leiomyoma and uterine leiomyoma; or
      • Multiple cutaneous leiomyoma; or
      • Kidney cancer and uterine leiomyomata

OR

--Renal tumor histology consistent with HLRCC including, but not limited to: Collecting Duct and/or Papillary, Type II

OR

--Are a relative (related by blood) of an individual with a confirmed or suspected diagnosis of HLRCC.

  • Participants must be >= 2 years of age.
  • All participants and parents/guardians, for children younger than 18 years of age, must sign an informed consent document indicating their understanding of the investigational nature and the risks of this study before any protocol related studies are performed.

EXCLUSION CRITERIA:

None

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: CASE_ONLY
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
1 / Individuals

Individuals with known or suspected Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC)

2 / Family Members

Family members (related by blood) of individuals who have or are suspected of having Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC)

3 / Non-Biologic Family Members

Spouses enrolled primarily for linkage analysis (Spouses have been removed from the inclusion criteria for this study. This closed cohort is for spouses previously enrolled on study.)

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Determine the incidence and characteristics of HLRCC-associated fumarate hydratase gene mutations.
기간: on-going

Molecular genetic differences between normal and tumorigenic fumarate hydratase (fumerase) mutations.

on-going
Determine the clinical manifestations of HLRCC
기간: on-going

Collection of blood, urine and/or benign and malignant tissue.

on-going
Determine if other genes cause HLRCC.
기간: on-going

Molecular genetic differences between normal and tumorigenic cells.

on-going
Determine genotype/phenotype correlations.
기간: on-going

Detection and expression analysis of gene(s).

on-going
Define the types and characteristics (including patterns of growth) of renal cancer associated with HLRCC.
기간: on-going

Detection and expression analysis of gene(s).

on-going
Define the risk of developing renal cancer, cutaneous leiomyoma and uterine leiomyoma in this hereditary cancer syndrome.
기간: on-going

Collection of blood, urine and/or benign and malignant tissue.

on-going

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: W. Marston Linehan, M.D., National Cancer Institute (NCI)

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2003년 2월 24일

연구 등록 날짜

최초 제출

2002년 12월 17일

QC 기준을 충족하는 최초 제출

2002년 12월 17일

처음 게시됨 (추정된)

2002년 12월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 10일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 7일

마지막으로 확인됨

2026년 11월 2일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 030066
  • 03-C-0066

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

All IPD recorded in the medical record will be shared with intramural investigators upon request. @@@@@@In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP.

IPD 공유 기간

Clinical data available during the study and indefinitely.@@@@@@Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.

IPD 공유 액세스 기준

Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.@@@@@@Genomic data are made available via dbGaP through requests to the data custodians.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .